Efficient and ligand-dependent regulated erythropoietin production by naked dna injection and in vivo electroporation.
The development of an in vivo gene transfer approach to deliver physiologic levels of recombinant proteins to the systemic circulation would represent a significant advance in the treatment of protein deficiencies-disorders. However, the ability to regulate transgene expression will become paramount for safety and efficacy in gene transfer therapy. We have described the construction of an efficient and ligand-dependently regulated erythropoietin (EPO) production system using naked plasmid and in vivo electroporation. Two plasmids, one encoding the chimeric GeneSwitch protein and the other encoding an inducible transgene for human EPO, were developed. Modulation of the level of secretion of EPO into the serum was achieved by intraperitoneal administration of mifepristone (MFP). Rats were divided into 4 groups: one group received EPO plasmid with MFP for 30 days, a second group received with EPO plasmid MFP for 9 days, a third group received EPO plasmid without MFP, and a fourth group received control plasmid. A pair of electrodes was inserted into the muscle of the right thigh and 100 micrograms of each plasmid was injected. In vivo electrporation (8 times at 100 V for 50 milliseconds) was performed. The presence of vector-derived EPO mRNA was detected by reverse transcriptase-polymerase chain reaction only in the EPO and MFP(+) group. The hematocrit levels increased continuously from the preinjection level of 42.7% to 53.8% on day 28 in the EPO and MFP(+) group. The serum EPO levels increased only in the EPO and MFP(+) group. There was no significant change in hematocrit levels and EPO levels in the EPO and MFP(-) group. These results demonstrate that EPO gene transfer with the GeneSwitch system by in vivo electroporation is a useful procedure for efficient and drug-dependent regulated delivery of EPO.
Terada
Y
Y
Homeostasis Medicine and Nephrology, Tokyo Medical and Dental University, Tokyo, Japan. yterada.kid@tmd.ac.jp
Tanaka
H
H
Okado
T
T
Inoshita
S
S
Kuwahara
M
M
Akiba
T
T
Sasaki
S
S
Marumo
F
F
D000818:Animals; D018274:Electroporation / Q000379:methods*; D004921:Erythropoietin / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism*; D018014:Gene Transfer Techniques; D006400:Hematocrit; D007273:Injections, Intramuscular; D008024:Ligands; D018482:Muscle, Skeletal / Q000166:cytology / Q000378:metabolism; D010957:Plasmids; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D013848:Thigh
D008024:Ligands; D011994:Recombinant Proteins; D004921:Erythropoietin